HomeArticlesToday's HighlightsBiogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity
Today's Highlights
Premium

Biogen and UCB Results: Phase 3 PHOENYCS GO Study Evaluating Dapirolizumab Pegol Demonstrated a Reduction in Systemic Lupus Erythematosus Disease Activity

Biogen & UCB Announcement Today, November 19, 2024, UCB (Euronext Brussels: ( UCB ) and Biogen ( BIIB ) presented detailed results from the Phase 3 PHOENYCS GO study evaluating dapirolizumab pegol ( D...
P

Prohost Biotech

1 min read
27
0

Unlock Premium Content

This article contains exclusive content for our premium subscribers. Join our community to access in-depth research, expert insights, and comprehensive analysis.

Unlimited articles
Expert analysis
Research reports

Comments (0)

Please sign in to join the discussion